Abstract 474P
Background
Good overall and disease-free survival for small primary lung cancers may be achieved with sublobar resections. These cancers presented as undiagnosed solitary lung nodule and may be difficult to localise intra-operatively due to their size or their ground glass nature, necessitating a greater anatomical resection. Our institution had adopted the use of image guided coil localisation since 2017 to aid the excision of such nodules. The localisation was performed on the same day just prior to the lung resection surgery. We aimed to share our experience with this technique.
Methods
We reviewed the outcomes of all patients who underwent surgical excision for undiagnosed solitary lung nodule between 2018 and 2021 and compared the efficacy with patients who had coil localisation and those who did not.
Results
182 consecutive patients were reviewed in our study. 36 patients (19.8%) underwent coil localisation whilst 146 patients (80.2%) did not. There was no significant difference in the pre-operative lung function between the 2 groups of patients. 88.5% of nodules were malignant and there was no significant difference in incidence between both groups (coil 91.7% vs no coil 87.7%, p = 0.368). Lung resection was performed via uniportal video assisted thoracoscopic (UVATS) in all coiling cases whilst 9 non-coiling cases (6.2%) had open thoracotomy. Patients who had coiling were more likely to underwent wedge resection than an anatomical resection (OR 2.14, 95% CI 1.62-2.82, p < 0.001).The conversion rate was lower in patients who had underwent coil localisation (OR 0.72, 95% CI 0.27-1.98) but this was not statistically significant (p = 0.367). All patients who underwent coil localisation reported clear margins on final histology. Patient who underwent coil localisation had a shorter length of stay (mean 3.44 +/- 2.92 days) than those who did not (mean 4.07 +/- 3.21 days) (p = 0.290). There was no significant difference in complications between both group of patients.
Conclusions
Both diagnostic and cure can be achieved via UVATS wedge resection with the aid of coil localisation. Our study demonstrated it as a safe and effective method of managing suspicious small primary lung cancers presenting as a small solitary lung nodule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract